SuperworthIncannex Healthcare EPS IXHL
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$1.75
- Latest quarter, Q4 FY26
- −$0.20
- Fiscal year 2026
- −$1.75
Incannex Healthcare's earnings per share was −$1.75 over the twelve months to Jun 30, 2026.
In its latest quarter, Q4 FY26, it was −$0.20.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$1.75 | n/a |
| FY2025 | −$36.17 | n/a |
| FY2024 | −$35.10 | n/a |
| FY2023 | −$99.60 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | −$0.20 | n/a | −$1.75 | |
| Q3 FY26 | −$0.35 | n/a | −$12.93 | |
| Q2 FY26 | −$0.60 | n/a | −$18.77 | |
| Q1 FY26 | −$0.60 | n/a | −$28.07 | |
| Q4 FY25 | −$11.38 | n/a | −$36.17 | |
| Q3 FY25 | −$6.19 | n/a | −$36.19 | |
| Q2 FY25 | −$9.90 | n/a | −$41.40 | |
| Q1 FY25 | −$8.70 | n/a | −$41.40 | |
| Q4 FY24 | −$11.40 | n/a | −$35.10 | |
| Q3 FY24 | −$11.40 | n/a | −$31.50 | |
| Q2 FY24 | −$9.90 | n/a | −$26.70 | |
| Q1 FY24 | −$2.40 | n/a | −$22.50 |
Against its peers
Companies in Drug Manufacturers - General nearest Incannex Healthcare's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IXHLIncannex Healthcare | −$1.75 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Incannex Healthcare
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.